Arcutis Biotherapeutics (ARQT) Expected to Announce Earnings on Tuesday

Key Points

• Arcutis Biotherapeutics is expected to announce its Q3 2025 earnings on October 28th, predicting an earnings per share of ($0.09) and revenue of $86.69 million.
• In the previous quarter, the company reported an earnings per share of ($0.13), exceeding estimates by $0.05, with revenue of $81.50 million, above analyst expectations.
• Insider trading activity has seen significant sales, with a total of 154,386 shares sold worth approximately $2.64 million over the past 90 days, indicating potential shifts in insider confidence.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) will likely be releasing its Q3 2025 results before the market opens on Tuesday, October 28th. Analysts expect Arcutis Biotherapeutics to post earnings of ($0.09) per share and revenue of $86.6910 million for the quarter. Interested persons may visit the the company's upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.05. Arcutis Biotherapeutics had a negative return on equity of 62.62% and a negative net margin of 35.40%.The firm had revenue of $81.50 million for the quarter, compared to analyst estimates of $72.70 million. On average, analysts expect Arcutis Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Arcutis Biotherapeutics Stock Performance

NASDAQ ARQT opened at $20.88 on Tuesday. The company has a quick ratio of 3.04, a current ratio of 3.20 and a debt-to-equity ratio of 0.77. Arcutis Biotherapeutics has a 52-week low of $8.03 and a 52-week high of $21.84. The business's 50-day moving average price is $17.77 and its 200 day moving average price is $15.40. The firm has a market cap of $2.50 billion, a P/E ratio of -27.84 and a beta of 2.06.

Insider Activity at Arcutis Biotherapeutics

In other news, insider Masaru Matsuda sold 36,130 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $16.16, for a total transaction of $583,860.80. Following the completion of the sale, the insider directly owned 161,234 shares in the company, valued at approximately $2,605,541.44. This trade represents a 18.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Patrick Burnett sold 2,438 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $15.57, for a total transaction of $37,959.66. Following the sale, the insider owned 104,811 shares of the company's stock, valued at approximately $1,631,907.27. The trade was a 2.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 154,386 shares of company stock worth $2,640,187. 9.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. CANADA LIFE ASSURANCE Co raised its position in shares of Arcutis Biotherapeutics by 101.5% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 25,829 shares of the company's stock worth $363,000 after purchasing an additional 13,013 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Arcutis Biotherapeutics by 278.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,414 shares of the company's stock worth $174,000 after purchasing an additional 9,135 shares during the last quarter. E Fund Management Co. Ltd. raised its position in shares of Arcutis Biotherapeutics by 14.7% during the 2nd quarter. E Fund Management Co. Ltd. now owns 17,184 shares of the company's stock worth $241,000 after purchasing an additional 2,197 shares during the last quarter. Oxford Asset Management LLP raised its position in shares of Arcutis Biotherapeutics by 9.1% during the 2nd quarter. Oxford Asset Management LLP now owns 23,271 shares of the company's stock worth $326,000 after purchasing an additional 1,947 shares during the last quarter. Finally, Lazard Asset Management LLC raised its position in shares of Arcutis Biotherapeutics by 3.2% during the 2nd quarter. Lazard Asset Management LLC now owns 386,011 shares of the company's stock worth $5,411,000 after purchasing an additional 11,928 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ARQT. Needham & Company LLC raised their price target on Arcutis Biotherapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, August 7th. The Goldman Sachs Group began coverage on Arcutis Biotherapeutics in a report on Friday, July 25th. They issued a "neutral" rating and a $18.00 price objective on the stock. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Arcutis Biotherapeutics in a report on Tuesday, October 14th. Wall Street Zen raised Arcutis Biotherapeutics from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Cowen reaffirmed a "buy" rating on shares of Arcutis Biotherapeutics in a report on Thursday, August 7th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $19.80.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.